Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

PLoS Biol. 2023 Apr 27;21(4):e3002081. doi: 10.1371/journal.pbio.3002081. eCollection 2023 Apr.


Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cell Line, Tumor
  • Enhancer of Zeste Homolog 2 Protein / genetics
  • Epigenesis, Genetic / drug effects
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Male
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / genetics
  • Prostatic Neoplasms, Castration-Resistant* / metabolism


  • Enhancer of Zeste Homolog 2 Protein
  • Histone Deacetylase Inhibitors
  • EZH2 protein, human